O Orexo AB
O
Chiusa
18.08 0.11
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
18.08
Massimo
18.54
Entrata | -68M -116M |
|---|---|
Vendite | -115M 3.3M |
EPS | 20.884 |
Margine di Profitto | -3,503.03 |
Dipendenti | 74 |
EBITDA | -262M -272M |
Utili prossimi | 16 lug 2026 |
|---|
Capitalizzazione di Mercato | -334M 700M |
|---|---|
Apertura precedente | 17.97 |
Chiusura precedente | 18.08 |
Orexo AB Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Notizie correlate
Confronto tra pari
Modifica del prezzo
Orexo AB Previsione
Notizie finanziarie
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$
Chi Siamo Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
